137 related articles for article (PubMed ID: 17431954)
1. Satraplatin for hormone-refractory prostate cancer.
Kerr C
Lancet Oncol; 2007 Apr; 8(4):290. PubMed ID: 17431954
[No Abstract] [Full Text] [Related]
2. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.
McKeage MJ
Drugs; 2007; 67(6):859-69. PubMed ID: 17428104
[TBL] [Abstract][Full Text] [Related]
3. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; CalabrĂ² F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
Sternberg CN; Whelan P; Hetherington J; Paluchowska B; Slee PH; Vekemans K; Van Erps P; Theodore C; Koriakine O; Oliver T; Lebwohl D; Debois M; Zurlo A; Collette L;
Oncology; 2005; 68(1):2-9. PubMed ID: 15741753
[TBL] [Abstract][Full Text] [Related]
5. Satraplatin for the therapy of castration-resistant prostate cancer.
Sonpavde G; Sternberg CN
Future Oncol; 2009 Sep; 5(7):931-40. PubMed ID: 19792961
[TBL] [Abstract][Full Text] [Related]
6. Current status and future prospects for satraplatin, an oral platinum analogue.
Choy H; Park C; Yao M
Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
[TBL] [Abstract][Full Text] [Related]
7. Satraplatin: an orally available platinum analog for the treatment of cancer.
Choy H
Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
[TBL] [Abstract][Full Text] [Related]
8. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
9. [Cycloplatam in the treatment of patients with disseminated prostatic cancer].
Matveev BP; Gorbunova VA; Smirnova NB; Zhumagazin ZhD; Bukharkin BV; Orel NF
Urol Nefrol (Mosk); 1996; (3):34-6. PubMed ID: 8928330
[TBL] [Abstract][Full Text] [Related]
10. Satraplatin in the treatment of hormone-refractory prostate cancer.
Sternberg CN
BJU Int; 2005 Nov; 96(7):990-4. PubMed ID: 16225514
[No Abstract] [Full Text] [Related]
11. Satraplatin: leading the new generation of oral platinum agents.
Bhargava A; Vaishampayan UN
Expert Opin Investig Drugs; 2009 Nov; 18(11):1787-97. PubMed ID: 19888874
[TBL] [Abstract][Full Text] [Related]
12. Current strategies in the treatment of metastatic hormone-refractory prostate cancer.
Ghosn M; Kattan J; Younes F
Tunis Med; 2005 Dec; 83 Suppl 12():74. PubMed ID: 16430073
[No Abstract] [Full Text] [Related]
13. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
14. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
[TBL] [Abstract][Full Text] [Related]
15. [Platinum drugs].
Kusaba H; Baba E
Nihon Rinsho; 2015 Feb; 73 Suppl 2():143-5. PubMed ID: 25831739
[No Abstract] [Full Text] [Related]
16. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
17. Castration refractory prostate cancer: cinderella finally comes to the ball.
Chowdhury S; Harper P; Powles T
Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
[No Abstract] [Full Text] [Related]
18. [The difficult choice: when not to treat. Hormone-refractory metastatic prostate cancer].
Bracarda S; Caserta C; Tonato M
Suppl Tumori; 2004; 3(4):S93. PubMed ID: 15206226
[No Abstract] [Full Text] [Related]
19. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
Ward JF
Nat Clin Pract Urol; 2006 Jun; 3(6):310-1. PubMed ID: 16763642
[No Abstract] [Full Text] [Related]
20. Phase II trial of carboplatin in patients with advanced melanoma.
Casper ES; Bajorin D
Invest New Drugs; 1990 May; 8(2):187-90. PubMed ID: 1696568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]